About ACEROpexa is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa's proprietary T-cell technology. The Company's leading therapy candidate, Tcelna(R), is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of secondary progressive MS. Tcelna consists of myelin-reactive T-cells, which are expanded ex vivo from the patient's peripheral blood and reintroduced into the patient in an attenuated form via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin for each individual patient.
|ETF Ticker||ETF Name||Net Assets||Net Assets Raw||# Holdings||# Holdings Raw||Weight||Weight Raw||Market Value||Market Value Raw|
|ProShares UltraPro Russell2000||92.7 M||9.26625E+07||2,001||2001||0.0%||2.20527E-06||639||639|
|ProShares Ultra Russell2000||175.1 M||1.75075E+08||1,999||1999||0.0%||3.15114E-06||1 K||1183|
|iShares Core S&P Total U.S. Stock Market ETF||24.5 B||2.44501E+10||3,561||3561||0.0%||0||1 K||1251|
|iShares Microcap ETF||812.4 M||8.12372E+08||1,387||1387||0.01%||0.0001||52 K||51653|
|iShares Russell 2000 ETF||45.6 B||4.55937E+10||1,988||1988||0.0%||0||384 K||383673|
|iShares Russell 2000 Growth ETF||9.2 B||9.19167E+09||1,154||1154||0.0%||0||153 K||153490|